Related references
Note: Only part of the references are listed.Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease
Rebecca L. Tisdale et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2022)
The Relationship Between Take-up of Prescription Drug Subsidies and Medicaid Among Low-Income Medicare Beneficiaries
Eric T. Roberts et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2021)
The Affordability of Guideline-Directed Medical Therapy Cost Sharing is a Critical Barrier to Therapy Adoption
Alexander T. Sandhu et al.
CIRCULATION (2021)
Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits
Yumin Gao et al.
AMERICAN HEART JOURNAL (2020)
Challenges and Potential Improvements to Patient Access to Pharmaceuticals Examples From Cardiology
Mitchell A. Psotka et al.
CIRCULATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates
Elias J. Dayoub et al.
CIRCULATION (2019)
Adoption of New Glucose-Lowering Medications in the US-The Case of SGLT2 Inhibitors: Nationwide Cohort Study
Rozalina G. McCoy et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2019)
Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data
Edward W. Gregg et al.
LANCET (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Prescriber Patterns of SGLT2i After Expansions of US Food and Drug Administration Labeling
Muthiah Vaduganathan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing
Gregory P. Hess et al.
CIRCULATION (2017)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Value-Based Cost Sharing In The United States And Elsewhere Can Increase Patients' Use Of High-Value Goods And Services
Sarah Thomson et al.
HEALTH AFFAIRS (2013)
Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs
Daniel Lakens
FRONTIERS IN PSYCHOLOGY (2013)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Lipid-lowering therapy with statins in high-risk elderly patients - The treatment-risk paradox
DT Ko et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Risk factors and secondary prevention in women with heart disease: The heart and estrogen/progestin replacement study
E Vittinghoff et al.
ANNALS OF INTERNAL MEDICINE (2003)
Share Paper
